BridgeBio Pharma, Inc. (2CL.F)

25,22 -0,38 (-1,48%) Börsenschluss: 03:57PM CEST

BridgeBio Pharma, Inc.

3160 Porter Drive
Suite 250
Palo Alto, CA 94304
United States
650 391 9740
https://bridgebio.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 550

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Neil Kumar Ph.D.	Co-Founder, President, CEO & Director	1,43M	N/A	1979
Dr. Charles J. Homcy M.D.	Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director	523,08k	N/A	1948
Dr. Frank P. McCormick Ph.D.	Co-Founder, Chairman of Oncology & Director	504,11k	N/A	1950
Dr. Brian C. Stephenson C.F.A., Ph.D.	CFO & Secretary	1,07M	N/A	1981
Dr. Richard H. Scheller Ph.D.	Chairman of Research & Development	473,32k	N/A	1953
Dr. Uma Sinha Ph.D.	Chief Scientific Officer	1,22M	N/A	1958
Grace Rauh	Vice President of Communications	N/A	N/A	N/A
Mr. Eli M. Wallace Ph.D.	Chief Scientific Officer of Oncology	N/A	N/A	1967
Dr. Thomas Trimarchi Ph.D.	Chief Product Officer	N/A	N/A	N/A
Dr. Eric Michael David J.D., M.D., Ph.D.	Chief Executive Officer of Gene Therapy	N/A	N/A	1972

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Corporate Governance

BridgeBio Pharma, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 10. Die grundlegenden Scores sind Audit: 3, Vorstand: 10, Shareholderrechte: 8, Kompensation: 10.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.